TGF-β Signaling and Resistance to Cancer Therapy
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The transforming growth factor β (TGF-β) pathway, which is well studied for its ability to inhibit cell proliferation in early stages of tumorigenesis while promoting epithelial-mesenchymal transition and invasion in advanced cancer, is considered to act as a double-edged sword in cancer. Multiple inhibitors have been developed to target TGF-β signaling, but results from clinical trials were inconsistent, suggesting that the functions of TGF-β in human cancers are not yet fully explored. Multiple drug resistance is a major challenge in cancer therapy; emerging evidence indicates that TGF-β signaling may be a key factor in cancer resistance to chemotherapy, targeted therapy and immunotherapy. Finally, combining anti-TGF-β therapy with other cancer therapy is an attractive venue to be explored for the treatment of therapy-resistant cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Although cancer immunotherapy has made impressive progress in the treatment of a number of solid tumors and hematologic malignancies (Tumeh et al., 2014; Cristescu et al., 2018; Rodig et al., 2018), challenges persist as only a subset of patients with solid tumors are able to benefit from immunotherapy, owing to multi…”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 10×
“Co-administration of TGF-β inhibitors and anti-PD-L1 antibody effectively reduced TGF-β signaling in stromal cells, resulting in improved T-cell penetration and more vigorous anti-tumor immunity to suppress urothelial tumor growth (Mariathasan et al., 2018).”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 2×
“Increasing evidence suggests that TGF-β signaling acts like a double-edged sword in tumor progression (Bierie and Moses, 2006; Massagué, 2008).”
BackgroundTransforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Self-citationTGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 9×
“In stratified rectal and genital epithelia lacking type II TGF-β receptor (TβRII) expression, TGF-β signaling is disrupted, leading to destabilized tissue homeostasis and the development of spontaneous SCCs in stratified epithelia (Guasch et al., 2007).”
BackgroundInfluentialFischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“Hyper-activation of MAPK signaling occurs frequently in human cancers, such as melanoma, colorectal cancer, thyroid carcinoma, and hepatic cancer (Fang and Richardson, 2005; Santarpia et al., 2012; Lee et al., 2020).”
BackgroundImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140 · cited 2×
“Another concern is that in clinical trials, the application of TGF-β inhibitors may result in off-target toxicity, especially cardiac toxicity (Turley et al., 2015) and dose-limiting toxicities (NCT01646203).”
BackgroundStromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · cited 5×
“A number of recent studies have shown that activation of transforming growth factor β (TGF-β) signaling was associated with drug resistance in a variety of cancers including melanoma (Sun et al., 2014), NSCLC (Soucheray et al.”
BackgroundInfluentialSmad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M. L., Greene, M. I., & Tone, M. (2008) · Nature Immunology · doi:10.1038/ni1549 · Cited by 807
Signaling Receptors for TGF-β Family Members
Heldin, C.-H., & Moustakas, A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022053 · Cited by 711
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674 · cited 5×
“SMAD4 deletion accelerates the transformation from premalignant to malignant phenotype in pancreatic progenitors harboring Kirsten rat sarcoma virus (KRAS) mutations (Bardeesy et al., 2006; Zhang et al., 2019a).”
BackgroundInfluentialKloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
Zhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., Wang, H., Fang, R., Bu, X., Cai, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10561 · Cited by 580
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539 · cited 1×
“In the past few decades, the dual role of TGF-β in tumorigenesis and tumor-suppression have been extensively studied (Roberts andWakefield, 2003; Levy and Hill, 2006; Massagué, 2008) and a growing body of literature elucidated that TGF-β/SMAD pathway was activated in multitherapy resistance.”
BackgroundTGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471 · cited 1×
“Using an in vitro reporter system for lineage tracing, Oshimori and his colleagues (Oshimori et al., 2015) showed that very few TGF-β-responding squamous cell carcinoma stem cells (SCC-SCs) were sensitive to cisplatin treatment, suggesting that TGF-β signaling pathway mediated primary resistance in…”
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · cited 2×
“Elevated expression of ZNF32 or reduced expression of MED12 up-regulate TGF-β signaling, resulting in MEK/ERK pathway activation to promote EGFRi-resistance in lung cancer (Huang et al., 2012; Li et al., 2016).”
BackgroundYao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325 · cited 1×
“Similarly, the combinations of anti-CTLA4-TβRII or anti-PDL1-TβRII elicited more pronounced anti-tumor responses than single treatments (Ravi et al., 2018).”
BackgroundTGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287 · cited 1×
“Other studies reported that TGF-β1 induced high expression of PD-1 and PD-L1 in T cells and tumor cells, respectively, to impair the anti-tumor activities of T cells and facilitate cancer immune evasion (Park et al., 2016; David et al., 2017; Tang et al., 2020).”
ResultTang, Y.-A., Chen, Y.-F., Bao, Y., Mahara, S., Yatim, S. M. J. M., Oguz, G., Lee, P. L., Feng, M., Cai, Y., Tan, E. Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801348115 · Cited by 277
Self-citationLind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · cited 10×
“…showed that combination treatment elicited higher anti-tumor activity in murine model and human cancer cell lines, such as breast cancer, colon cancer, SCC (Lan et al., 2018; Mariathasan et al., 2018; Tauriello et al., 2018; Dodagatta-Marri et al., 2019; Principe et al., 2019; Lind et al., 2020).”
BackgroundInfluentialMicropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102190 · Cited by 243
Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224 · cited 10×
“Blocking TGF-β signaling in CD4+ T cells but not CD8+ T cells restrained tumor growth by remodeling the TME and inducing tumor vasculature reorganization, leading to cancer cell death; this process was dependent on the TH2 cytokine interleukin-4 (IL-4), but not the TH1 cytokine interferon-γ (IFN-γ).”
BackgroundInfluentialDavid, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177 · cited 8×
“In stratified rectal and genital epithelia lacking type II TGF-β receptor (TβRII) expression, TGF-β signaling is disrupted, leading to destabilized tissue homeostasis and the development of spontaneous SCCs in stratified epithelia (Guasch et al., 2007).”
BackgroundInfluentialImpairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149 · cited 1×
“TGFβ secreted by tumor cells facilitates the escape of tumor cells from immune surveillance by directly driving the conversion of NK cells into innate lymphoid cells type 1 (ILC1), which lacks cytotoxic function, or by impairing NKG2D-mediated cytotoxicity (Cortez et al., 2017; Gao et al., 2017; Lazarova and Steinle,…”
BackgroundTGF-β: An emerging player in drug resistance
Brunen, D., Willems, S., Kellner, U., Midgley, R., Simon, I., & Bernards, R. (2013) · Cell Cycle · doi:10.4161/cc.26034 · Cited by 124
Lambies, G., Miceli, M., Martínez-Guillamon, C., Olivera-Salguero, R., Peña, R., Frías, C.-P., Calderón, I., Atanassov, B. S., Dent, S. Y. R., Arribas, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0753 · Cited by 99
Quan, Q., Zhong, F., Wang, X., Chen, K., & Guo, L. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15442985680348 · Cited by 29 · cited 6×
“A number of recent studies have shown that activation of transforming growth factor β (TGF-β) signaling was associated with drug resistance in a variety of cancers including melanoma (Sun et al., 2014), NSCLC (Soucheray et al., 2015), breast cancer (Palomeras et al., 2019), hepatocellular carcinoma (HCC) (Bhagyaraj et…”
BackgroundInfluential
Cited by
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
Metadata
- Authors
- Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2021-11-30
- Volume
- 9
- Pages
- 786728-786728
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3217209761
- Cited by
- 191
- References
- 36
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.